Literature DB >> 16645238

Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis.

Basak Oyan1, Yener Koc, Salih Emri, Emin Kansu.   

Abstract

Despite use of combined immunosuppressive agents, prognosis of patients developing pulmonary manifestations of chronic graft-vs-host disease (cGVHD) following allogeneic stem cell transplantation (SCT) still remains poor. We present a male patient who developed pulmonary cGVHD in the form of bronchiolitis obliterans organizing pneumonia (BOOP) following allogeneic SCT for acute myelogenous leukemia. The patient developed progressive course despite use of a combination of immunosuppressive agents including high-dose prednisone, cyclosporin-A, and mycophenolate mofetil in addition to steroid-related complications. A remarkable clinical response to extracorporeal photopheresis (ECP) was observed, allowing minimization of immunosuppressive therapy and discontinuation of cyclosporin-A. Pulmonary functions and carbon monoxide diffusion capacity (DLCO) gradually improved and stabilized, but did not return to pretransplant baseline levels.

Entities:  

Mesh:

Year:  2006        PMID: 16645238     DOI: 10.1385/MO:23:1:125

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  16 in total

1.  Bronchiolitis obliterans organizing pneumonia and chronic graft-versus-host disease in a child after allogeneic bone marrow transplantation.

Authors:  I Kleinau; A Perez-Canto; H J Schmid; A Grassot; D Staab; H Renz; G Henze; U Wahn; K Paul
Journal:  Bone Marrow Transplant       Date:  1997-04       Impact factor: 5.483

2.  Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation.

Authors:  S P Kantrow; R C Hackman; M Boeckh; D Myerson; S W Crawford
Journal:  Transplantation       Date:  1997-04-27       Impact factor: 4.939

3.  Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD)

Authors:  F J Child; R Ratnavel; P Watkins; D Samson; J Apperley; J Ball; P Taylor; R Russell-Jones
Journal:  Bone Marrow Transplant       Date:  1999-05       Impact factor: 5.483

Review 4.  Interstitial pneumonitis following bone marrow transplantation: pathogenesis and therapeutic considerations.

Authors:  B L Cardozo; A Hagenbeek
Journal:  Eur J Cancer Clin Oncol       Date:  1985-01

5.  Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation.

Authors:  A Palmas; A Tefferi; J L Myers; J P Scott; S J Swensen; M G Chen; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; M R Litzow
Journal:  Br J Haematol       Date:  1998-03       Impact factor: 6.998

Review 6.  Graft-versus-host disease.

Authors:  D Bron
Journal:  Curr Opin Oncol       Date:  1994-07       Impact factor: 3.645

7.  Interstitial pneumonitis, pulmonary fibrosis, and chronic graft-versus-host disease.

Authors:  E B Kaplan; G G Pietra; C S August
Journal:  Bone Marrow Transplant       Date:  1992-01       Impact factor: 5.483

8.  Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course.

Authors:  J G Clark; S W Crawford; D K Madtes; K M Sullivan
Journal:  Ann Intern Med       Date:  1989-09-01       Impact factor: 25.391

9.  Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth; Todd E DeFor; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

Review 10.  The lung as a critical organ in marrow transplantation.

Authors:  K Quabeck
Journal:  Bone Marrow Transplant       Date:  1994       Impact factor: 5.483

View more
  1 in total

Review 1.  Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.

Authors:  G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.